Publications
Explore our latest scientific posters, presentations, and peer-reviewed publications that highlight the potential of our therapies to advance treatment for immune-mediated diseases.
Budoprutug
Poster: Budoprutug, A Low-Fucosylated Anti-CD19 Monoclonal Antibody, In Adults With Primary Immune Thrombocytopenia: Initial Phase 1B Study Results
Presented at the EHA Congress June 11, 2026
Poster: PrisMN: Phase 2 Study to Evaluate the Safety and Efficacy of Budoprutug, a Low-Fucosylated Anti-CD19 mAb, in Primary Membranous Nephropathy »
Presented at the 63rd ERA Congress Glasgow & Virtual, June 3-6, 2026
Published Abstract: Long-Term Remission of Proteinuria in Primary Membranous Nephropathy After Four Doses of Budoprutug, a Novel Anti-CD19 Monoclonal Antibody »
Published as part of the American Society of Nephrology (ASN) Kidney Week, November 5-9, 2025
Poster: A Tunable Scalable Platform for Precise Fucosylation Control to Enhance Efficacy of Therapeutic Antibodies: Application to Clinical Manufacturing of Budoprutug »
Presented at PEGS Boston – The Essential Protein Engineering & Cell Therapy Summit, May 12-16, 2025
Poster: A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy (pMN) »
Presented at the American Society of Nephrology (ASN) Kidney Week, October 23-24, 2024
CLYM116
Focused Oral: CLYM116, a Novel ‘Sweeper’ Anti-APRIL mAb: Extrapolation of PK and Ig Suppression from NHPs to Healthy Volunteers and Initial Phase 1 Data
Presented at the 63rd ERA Congress Glasgow & Virtual, June 3-6, 2026
Poster: Development and Characterization of CLYM116, A Novel FC-Engineered anti-APRIL mAb with pH-Dependent Binding for IgA Nephropathy
Presented at the American Society of Nephrology (ASN) Kidney Week, November 5-9, 2025